바이오테크 보도자료
-
- Linesight Poised for Future Global Expansion With New CEO
- Multinational consultancy firm, Linesight, announced today that it is promoting Paul Boylan to the position of Chief Executive Officer (CEO) and welcoming Tom Dempsey as COO. Boylan has been appointed as the new Chief Executive Officer (CEO) and w...
- 2021년 02월 04일
-
- Data at EAHAD 2021 Highlight Value of Takeda’s Leading Hematology Portfolio in Clinical Settings and Commitment to Patient-Focused Advancements
- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”) today announced that 14 abstracts from the company’s Hematology portfolio and pipeline are being presented as electronic posters at the Virtual European Association for Haemophi...
- 2021년 02월 03일
-
- Vifor Pharma to propose Dr Alexandre LeBeaut as Board member
- Regulatory News: Vifor Pharma today announced that the Board of Directors will propose Dr Alexandre LeBeaut for election to the Board at the next Annual General Meeting on 6 May 2021. Jacques Theurillat, Chairman of Vifor Pharma, commented: “We ar...
- 2021년 02월 02일
-
- Takeda Completes Sale of TachoSil® to Corza Health
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has completed the previously announced sale of TachoSil® Fibrin Sealant Patch (“TachoSil®”) to Corza Health, Inc. (“Corza”) for €350 million. TachoSil® is...
- 2021년 02월 01일
-
- Takeda Completes Sale of Select OTC and Non-Core Assets to Hypera Pharma
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products sold in Latin America to Hypera S.A. (“Hypera Pharma”) for a total value of $825...
- 2021년 02월 01일
-
- Thousand Oaks Biopharmaceuticals Inked a Joint Venture Agreement with Korea’s WSG Group
- January 2021, Thousand Oaks Biopharmaceuticals Group (“Thousand Oaks”) announced that it had signed a Joint Venture agreement with WSG Group in Busan, Korea, to establish a bioprocess solution joint venture (including cell culture media, single-us...
- 2021년 01월 29일
-
- Takeda Presents Positive Results For Mobocertinib in Patients with EGFR Exon20 insertion+ mNSCLC Who Received Prior Platinum-based Chemotherapy
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced new data from the Phase 1/2 trial of mobocertinib (TAK-788) orally administered in previously treated patients with epidermal growth factor receptor (EGFR) Exon20...
- 2021년 01월 29일
-
- Takeda Achieved Carbon Neutrality in 2020
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it achieved carbon neutrality in its value chain for its fiscal year 2019. This achievement was delivered by a continued focus on internal energy conservatio...
- 2021년 01월 28일
-
- Takeda Achieves Industry-Leading Positions in 2021 Access to Medicine Index
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) has earned an industry-leading position within the 2021 Access to Medicine (AtM) Index published today. Specifically the company achieved notable, high scores in all three techni...
- 2021년 01월 27일
-
- Takeda Named Global Top Employer for Fourth Consecutive Year
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it is one of only 16 companies to achieve global Top Employer® certification for 2021. In addition to receiving the global certification for the fourth conse...
- 2021년 01월 25일
-
- ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment
- ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) approved Cabenuva, the first an...
- 2021년 01월 22일
전시회
